
### [MONDO:0019296](http://purl.obolibrary.org/obo/MONDO_0019296)
**Label:** subcutaneous tissue disease

**Subclasses:** [MONDO:0019599](http://purl.obolibrary.org/obo/MONDO_0019599) (primary lipodystrophy), [MONDO:0016584](http://purl.obolibrary.org/obo/MONDO_0016584) (mandibuloacral dysplasia), [MONDO:0020087](http://purl.obolibrary.org/obo/MONDO_0020087) (genetic lipodystrophy), [MONDO:0018883](http://purl.obolibrary.org/obo/MONDO_0018883) (Berardinelli-Seip congenital lipodystrophy), [MONDO:0020088](http://purl.obolibrary.org/obo/MONDO_0020088) (familial partial lipodystrophy), [MONDO:0020089](http://purl.obolibrary.org/obo/MONDO_0020089) (acquired lipodystrophy), [MONDO:0007908](http://purl.obolibrary.org/obo/MONDO_0007908) (multiple symmetric lipomatosis), [MONDO:0019194](http://purl.obolibrary.org/obo/MONDO_0019194) (localized lipodystrophy), 

**Corr. equiv. classes:** [OMIM:151800](http://purl.obolibrary.org/obo/OMIM_151800), [Orphanet:2398](http://www.orpha.net/ORDO/Orphanet_2398), [Orphanet:98305](http://www.orpha.net/ORDO/Orphanet_98305), [Orphanet:79088](http://www.orpha.net/ORDO/Orphanet_79088), [Orphanet:528](http://www.orpha.net/ORDO/Orphanet_528), [Orphanet:98306](http://www.orpha.net/ORDO/Orphanet_98306), [Orphanet:98307](http://www.orpha.net/ORDO/Orphanet_98307), [Orphanet:90970](http://www.orpha.net/ORDO/Orphanet_90970), [Orphanet:2457](http://www.orpha.net/ORDO/Orphanet_2457), 

**Class expressions from DL-Learner:**

- [HP:0003077](http://purl.obolibrary.org/obo/HP_0003077) (Hyperlipidemia) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0000956](http://purl.obolibrary.org/obo/HP_0000956) (Acanthosis nigricans) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0000855](http://purl.obolibrary.org/obo/HP_0000855) (Insulin resistance) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0011014](http://purl.obolibrary.org/obo/HP_0011014) (Abnormal glucose homeostasis) and [HP:0011805](http://purl.obolibrary.org/obo/HP_0011805) (Abnormality of muscle morphology) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0011014](http://purl.obolibrary.org/obo/HP_0011014) (Abnormal glucose homeostasis) and [HP:0011368](http://purl.obolibrary.org/obo/HP_0011368) (Epidermal thickening) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0011013](http://purl.obolibrary.org/obo/HP_0011013) (Abnormality of carbohydrate metabolism/homeostasis) and [HP:0011805](http://purl.obolibrary.org/obo/HP_0011805) (Abnormality of muscle morphology) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0011013](http://purl.obolibrary.org/obo/HP_0011013) (Abnormality of carbohydrate metabolism/homeostasis) and [HP:0011368](http://purl.obolibrary.org/obo/HP_0011368) (Epidermal thickening) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0003119](http://purl.obolibrary.org/obo/HP_0003119) (Abnormality of lipid metabolism) and [HP:0011805](http://purl.obolibrary.org/obo/HP_0011805) (Abnormality of muscle morphology) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0003119](http://purl.obolibrary.org/obo/HP_0003119) (Abnormality of lipid metabolism) and [HP:0011368](http://purl.obolibrary.org/obo/HP_0011368) (Epidermal thickening) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0003077](http://purl.obolibrary.org/obo/HP_0003077) (Hyperlipidemia) and [HP:0011805](http://purl.obolibrary.org/obo/HP_0011805) (Abnormality of muscle morphology) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0003077](http://purl.obolibrary.org/obo/HP_0003077) (Hyperlipidemia) and [HP:0011368](http://purl.obolibrary.org/obo/HP_0011368) (Epidermal thickening) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0003077](http://purl.obolibrary.org/obo/HP_0003077) (Hyperlipidemia) and [HP:0011121](http://purl.obolibrary.org/obo/HP_0011121) (Abnormality of skin morphology) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0003077](http://purl.obolibrary.org/obo/HP_0003077) (Hyperlipidemia) and [HP:0011014](http://purl.obolibrary.org/obo/HP_0011014) (Abnormal glucose homeostasis) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0003077](http://purl.obolibrary.org/obo/HP_0003077) (Hyperlipidemia) and [HP:0011013](http://purl.obolibrary.org/obo/HP_0011013) (Abnormality of carbohydrate metabolism/homeostasis) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%
- [HP:0003011](http://purl.obolibrary.org/obo/HP_0003011) (Abnormality of the musculature) and [HP:0003077](http://purl.obolibrary.org/obo/HP_0003077) (Hyperlipidemia) and [HP:0100578](http://purl.obolibrary.org/obo/HP_0100578) (Lipoatrophy) 66.67%


